Indication selection assessment for clinical stage oncology small molecule

Challenge: A venture capital firm was interested in an independent indication selection strategic assessment of a clinical stage small molecule oncology asset they had invested in, based on the...
Learn More

Opportunity mapping in myelofibrosis for phase II product

Challenge: An inflammation and oncology-focused biotech company was looking to expand the clinical footprint of one of its phase II products. Our client was discussing the potential positioning of...
Learn More

Due diligence on a reverse merger candidate with pipeline of IND-ready compounds

Challenge: A NASDAQ-listed biotech asked Alacrita to conduct a technical due diligence on a prospect reverse merger candidate. After screening numerous companies, our client identified a strong...
Learn More

Building Target Product Profiles and conducting rNPV valuations of lead assets

Challenge: A clinical stage company developing small molecules to treat fibrotic diseases engaged Alacrita to quantify the value potential of their lead asset in idiopathic pulmonary fibrosis (IPF),...
Learn More

Strategic analysis of preclinical data for a lipid combination treatment

Challenge: A European biopharma company developing synthetic lipids required a critical appraisal of data generated by a University research group using natural lipids in oncology. It wished to...
Learn More

Clinical development strategy & plan for novel small molecule

Challenge: For a leading university with an early stage novel small molecule to treat prostate cancer, Alacrita was asked to validate a development plan in order to support activities for securing...
Learn More

Interim Chief Medical Officer for oncology company developing small molecules

Challenge: Alacrita provided interim chief medical officer support to an oncology company over the course of two years. The company was a developing a portfolio of first in class small molecules to...
Learn More

CMC & manufacturing support for biotech developing a novel small molecule

Challenge A biotech company was developing its first oral compound — a novel small molecule. The company needed support in taking the compound to first-in-man studies and Phase II clinical trials.
Learn More
1